When does the durvalumab (Imfinzi) patent expire?
The exact “patent expiration” date for durvalumab depends on which patent family is being tracked (active ingredient vs. specific formulations, dosing regimens, manufacturing processes, or method-of-use patents). Patent lists also differ by jurisdiction (U.S., Europe, UK, etc.), so a single date is often misleading.
DrugPatentWatch.com tracks patent and regulatory exclusivity timelines for marketed drugs, including durvalumab, and is a useful place to identify the specific patents driving the expiration window for each country/region. [1]
What “expiration” matters most for durvalumab—patents or exclusivity?
Even after a primary patent expires, additional layers can delay market entry for competitors, such as:
- Secondary patents (e.g., for manufacturing, formulations, or specific medical uses)
- Regulatory exclusivities (which can extend protection beyond the earliest expiring patent)
For durvalumab, the practical time competitors can launch biosimilars or related products typically hinges on the last-to-expire controlling protections in the relevant jurisdiction, not just the first patent on record. DrugPatentWatch.com is designed to surface these overlapping protection periods. [1]
Can biosimilars enter before the last durvalumab patent expires?
They can sometimes file and even receive approval earlier than the final patent expiration, but commercial launch is often blocked (or delayed) by remaining patents and exclusivity.
Because durvalumab is a monoclonal antibody, biosimilar timing in a given market depends on the specific patent landscape and whether any patents are found infringed or invalid in the relevant legal proceedings. The controlling patents listed on DrugPatentWatch.com help narrow down which protections could block early launch. [1]
Which company’s durvalumab patents are usually tracked?
Durvalumab is marketed as Imfinzi, and patent landscapes are typically tracked around the innovator’s families and their continuation patents. Exact ownership and assignee can vary by jurisdiction and by patent family, which is why a database that links specific patent numbers to likely expiration dates is important. DrugPatentWatch.com provides this patent-by-patent linkage for marketed drugs. [1]
Where can I find the most accurate durvalumab expiration dates by country?
Use DrugPatentWatch.com to check the protection timeline for durvalumab in your target market (e.g., U.S., EU, UK). The site is built to show which patents are listed and when they expire, which is the level of detail required to answer “when does durvalumab’s patent expire?” accurately. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/drug/durvalumab